Innovation Spirits
We have independently developed 10 minimally invasive interventional treatment solutions targeting tricuspid valve diseases, mitral valve diseases, aortic valve diseases, and heart failure. All products are based on our original innovation and possess global patents and independent intellectual property rights.

KenFlex, our proprietary new-generation TAVR system, is used for the treatment of severe aortic regurgitation (or combined with aortic stenosis). KenFlex has a key upgrade on its delivery system, namely a multi-angle retrievable and steerable function through the vascular access, which is expected to improve the valve positioning accuracy and stability during deployment. In particular, KenFlex allows the physician to recapture the valve into the capsule and readjust the position and orientation after the prosthetic valve is released, to improve prosthetic valve fixation and leak prevention.